ACHR/WS Market Analysis

Overview

Fundamentals

P/E ratio
EPS (TTM)0.0% YoY
Profit margin0.0%NONE
Market cap

Valuation

Forward P/E
PEG ratio
P/B
P/S (TTM)
EV/EBITDA

Profitability & growth

ROE (TTM)
0.0%
Operating margin
0.0%
Revenue growth YoY
0.0%
Dividend yield
Beta

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 2 · 27 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About ACHR-WS

Achieve Life Sciences, Inc. (Ticker: ACHR-WS) is a clinical-stage biopharmaceutical firm dedicated to revolutionizing smoking cessation and nicotine addiction treatment through its lead therapeutic candidate, cytisine. Tackling a critical public health challenge, Achieve seeks to redefine nicotine replacement strategies by focusing on enhanced efficacy and patient outcomes. The company’s strategic partnerships and active product pipeline development further solidify its role in the rapidly growing health sector, which increasingly demands innovative cessation alternatives. Committed to…

Classification

Sector
None
Industry
None
Exchange
NYSE
Country
USA
Currency
USD

Company profile

HQ
NONE
Latest quarter
Shares outstanding$0
52W high$14.62
52W low$4.61

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer